Document Detail


Declining prevalence of hepatitis B virus infection in Catalonia (Spain) 12 years after the introduction of universal vaccination.
MedLine Citation:
PMID:  18045753     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
AIMS: To analyze the prevalence of hepatitis B virus infection markers and hepatitis B vaccination in a representative sample of the juvenile and adult population of Catalonia and to evaluate the changes with respect to seroepidemiological surveys carried out in 1989 and 1996. DESIGN: In all subjects anti-HBc and anti-HBs antibodies and HBsAg were determined using an ELISA test. The possible association between sociodemographic variables and the prevalence of markers was analysed by calculating the adjusted odd ratio (simple logistic regression). SETTING: The study was carried out in 2002 in representative samples of the juvenile (5-14 years) and adult population (>or= 15 years) of Catalonia (Spain). MAIN RESULTS: In 2002 the global prevalence of HBsAg+ was 0.7% (95% CI: 0.4-1.0) and that of anti-HBc+ 8.7% (95% CI: 7.6-9.8), values higher than those obtained in 1989 of 1.5% (95% CI: 1.0-2.1) and 15.6 (95% CI: 13.9-17.3). The prevalence of markers of infection increased with age. The only sociodemographic variable significantly associated with the prevalence of hepatitis B virus infection was the place of birth. The risk of infection was twice as high in subjects born outside Catalonia (p<0.01), adjusted OR 2.0 (95% CI: 1.34-2.98) compared with those born in Catalonia. CONCLUSIONS: The results of this study show that the prevalence of hepatitis B virus infection (anti-HBc+) in Catalonia (Spain) is currently the lowest it has ever been and suggest that there has been a change in the pattern of endemicity of hepatitis B virus infection in Catalonia, which has become a country of low endemicity.
Authors:
L Salleras; A Domínguez; M Bruguera; P Plans; J Costa; N Cardeñosa; J Batalla; A Plasència
Related Documents :
1744423 - Conserved core protein sequences in hepatitis b virus infected patients without anti-hbc.
936273 - The prevalence of hepatitis-b antigen (hb s ag) and its antibody (anti-hb s) among lond...
19935663 - Hla-c cell surface expression and control of hiv/aids correlate with a variant upstream...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2007-11-05
Journal Detail:
Title:  Vaccine     Volume:  25     ISSN:  0264-410X     ISO Abbreviation:  Vaccine     Publication Date:  2007 Dec 
Date Detail:
Created Date:  2007-12-10     Completed Date:  2008-02-21     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8406899     Medline TA:  Vaccine     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  8726-31     Citation Subset:  IM    
Affiliation:
Department of Public Health, University of Barcelona, Barcelona, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Age Factors
Aged
Aged, 80 and over
Child
Child, Preschool
Enzyme-Linked Immunosorbent Assay
Female
Hepatitis B / epidemiology*
Hepatitis B Antibodies / blood
Hepatitis B Surface Antigens / blood
Hepatitis B Vaccines / immunology*
Hepatitis B virus / immunology*
Humans
Male
Middle Aged
Prevalence
Seroepidemiologic Studies
Spain / epidemiology
Chemical
Reg. No./Substance:
0/Hepatitis B Antibodies; 0/Hepatitis B Surface Antigens; 0/Hepatitis B Vaccines

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Construction and preclinical evaluation of recombinant Peru-15 expressing high levels of the cholera...
Next Document:  Phenotypic changes in the Japanese encephalitis virus after one passage in Neuro-2a cells: generatio...